<div id="readability-page-1"><p>Coldstream Capital Management Inc. lessened its stake in shares of  Zoetis Inc. (NYSE:ZTS - Free Report) by 83.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor  owned 5,727 shares of the company's stock after selling 28,756 shares during the quarter. Coldstream Capital Management Inc.'s holdings in Zoetis were worth $721,000 as of its most recent filing with the SEC.</p><ul><li>Which Pet Stock Should Get Your Tail Wagging in 2024?</li></ul><p>Other large investors also recently made changes to their positions in the company. Global Wealth Strategies &amp; Associates bought a new stake in shares of  Zoetis during the 4th quarter worth about $25,000.  Lodestone Wealth Management LLC bought a new stake in  Zoetis during the 4th quarter valued at approximately $30,000.  KERR FINANCIAL PLANNING Corp bought a new stake in  Zoetis during the 3rd quarter valued at approximately $31,000.  Holos Integrated Wealth LLC bought a new stake in  Zoetis during the 4th quarter valued at approximately $32,000.  Finally, Elyxium Wealth LLC bought a new stake in  Zoetis during the 4th quarter valued at approximately $32,000. Institutional investors own  92.80% of the company's stock. </p><h2>Insider Activity</h2><p>In other news, Director Paul Bisaro acquired 2,000 shares of the stock in a transaction dated Wednesday, May 13th. The shares were acquired at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the transaction, the director owned 27,862 shares in the company, valued at approximately $2,114,168.56. This trade represents a 7.73% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Frank A. Damelio acquired 6,650 shares of the stock in a transaction dated Wednesday, May 13th. The shares were purchased at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the transaction, the director owned 21,458 shares of the company's stock, valued at $1,617,718.62. This trade represents a 44.91% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders have bought 11,650 shares of company stock worth $886,384. Company insiders own  0.22% of the company's stock. </p><h2>Zoetis Stock Performance</h2><ul><li>MarketBeat Week in Review – 07/31 - 08/04</li></ul><p>ZTS opened at $79.48 on Thursday. The stock has a market cap of $33.32 billion, a PE ratio of 13.18, a P/E/G ratio of 1.31 and a beta of 0.87. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. Zoetis Inc. has a 1 year low of $72.38 and a 1 year high of $172.23. The stock's 50 day simple moving average is $105.95 and its 200-day simple moving average is $117.60. </p><p>Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.60 by ($0.07). The firm had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business's revenue for the quarter was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS.  Sell-side analysts forecast that  Zoetis Inc. will post 6.88 EPS for the current year. </p><h2>Zoetis Announces Dividend</h2><ul><li>Rising Dividend Make Zoetis a Doggone Winner</li></ul><p>The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be given a dividend of $0.53 per share. The ex-dividend date is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.7%. Zoetis's payout ratio is currently 35.16%. </p><h2>Analyst Ratings Changes</h2><p>Several brokerages recently weighed in on ZTS. JPMorgan Chase &amp; Co. decreased their target price on Zoetis from $190.00 to $130.00 and set an &#34;overweight&#34; rating for the company in a research note on Friday, May 8th. Argus  restated a &#34;hold&#34; rating on shares of Zoetis in a research note on Wednesday. Weiss Ratings downgraded Zoetis from a &#34;hold (c-)&#34; rating to a &#34;sell (d+)&#34; rating in a research note on Friday, March 27th. Wall Street Zen downgraded Zoetis from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, May 2nd. Finally, Bank of America increased their target price on Zoetis from $135.00 to $140.00 and gave the company a &#34;neutral&#34; rating in a research note on Friday, February 13th. Six analysts have rated the stock with a Buy rating, eight have assigned  a Hold rating and one  has assigned  a Sell rating to the company's stock. According to MarketBeat, Zoetis presently has an average rating of &#34;Hold&#34; and an average price target of $133.92.</p><p><b>Read Our Latest Report on ZTS</b></p><h2>Zoetis Profile</h2> (Free Report)<p>Zoetis Inc <span>NYSE: ZTS<span></span></span> is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.  </p><p>Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Zoetis</li><li>Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak</li><li>TeraWulf Bets on Power Infrastructure to Lead AI Build-Out</li><li>Amazon's Alexa for Shopping Strengthens an Already Strong Bull Case</li><li>Keysight: The AI and Defense Stock Seeing Big Price Target Boosts</li></ul><p><strong>Want to see what other hedge funds are holding ZTS?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVpUUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVpUUw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Zoetis Right Now?</h2><p>Before you consider Zoetis, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.</p><p>While Zoetis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Coldstream Capital Management Inc. reduced its stake in Zoetis Inc. by 83.4%, selling 28,756 shares in Q4, leaving it with 5,727 shares valued at $721,000. Other investors also increased their stakes. Zoetis reported Q1 earnings of $1.53 EPS, missing estimates, and announced a quarterly dividend of $0.53 per share. Analysts have varied ratings on the stock, with JPMorgan lowering its target price from $190 to $130.</p>

Market Beat

Zoetis

iShares Biotechnology ETF

VanEck Biotech ETF

iShares US Pharma

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

iShares Global Healthcare

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

VG Health

Invesco Nasdaq Biotechnology ETF

Health Care Select Sector SPDR

JPMorgan Chase

Bank of America

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Coldstream Capital Management Inc. Sells 28,756 Shares of Zoetis Inc. $ZTS